Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 11/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.60 |
| ▸ | DYRK2 | Q92630 | 7/20 | 0.60 |
| ▸ | GRK5 | P34947 | 2/20 | 0.60 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.58 |
| ▸ | ATR | Q13535 | 1/20 | 0.58 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 6/20 | 0.56 |
| ▸ | DYRK3 | O43781 | 5/20 | 0.56 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.56 |
| ▸ | CDK2 | P24941 | 5/20 | 0.56 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.56 |
| ▸ | CDK9 | P50750 | 4/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236203 | 0.87 | DYRK1A (0.62) | FYNDYRK1ADYRK2GRK5CDK5 | |
| SCHEMBL3517595 | 0.84 | FYN (0.90) | FYNGRK5PIK3CAATR | |
| SCHEMBL2239646 | 0.82 | DYRK1A (0.56) | FYNDYRK1ADYRK2PIK3CAATR | |
| SCHEMBL15288602 | 0.82 | DYRK1A (0.70) | FYNDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL2948779 | 0.80 | DYRK1A (0.68) | FYNDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL16331572 | 0.80 | FYN (1.00) | FYNGRK5PIK3CAATR | |
| SCHEMBL28404217 | 0.79 | DYRK1A (0.68) | FYNDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL102796 | 0.79 | DYRK1A (0.71) | FYNDYRK1ADYRK2PIK3CACDK5 | |
| SCHEMBL102252 | 0.79 | DYRK1A (0.72) | FYNDYRK1ADYRK2CDK5CDK5R1 | |
| SCHEMBL21672006 | 0.78 | DYRK1A (0.71) | FYNDYRK1ADYRK2PIK3CACDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221817-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS POTENT MODULATORS OF THE HIPPO-YAP SIGNALING PATHWAY LATS1/2 KINASES | Nivien Therapeutics Compny (US) | 2021-07-22 | — | — | US | disclosed |
| US-20210221817-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS POTENT MODULATORS OF THE HIPPO-YAP SIGNALING PATHWAY LATS1/2 KINASES | Nivien Therapeutics Compny (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2020047037-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS POTENT MODULATORS OF THE HIPPO-YAP SIGNALING PATHWAY LATS1/2 KINASES | NIVIEN THERAPEUTICS COMPANY (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047037-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS POTENT MODULATORS OF THE HIPPO-YAP SIGNALING PATHWAY LATS1/2 KINASES | NIVIEN THERAPEUTICS COMPANY (US) | 2020-03-05 | — | — | WO | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221817-A1 | NOVEL HETEROAROMATIC COMPOUNDS AS POTENT MODULATORS OF THE HIPPO-YAP SIGNALING PATHWAY LATS1/2 KINASES | LATS1, LATS2, YAP1 | FYN 97/4885DYRK1A 239/4885DYRK2 209/4885 |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | FYN 425/4885DYRK1A 2632/4885DYRK2 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.